HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is based in Port Moody, Canada.
| 0.005 | |
| 0.005 | |
| - | |
| 0.005 | |
| 0.005 | |
| 0.005-0.096 | |
| 653 K | |
| 14 739 K | |
| 587 K | |
| -0.0528 | |
| -0.767 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
VANCOUVER, BC / ACCESSWIRE / October 31, 2022 / The Power Play by The Market Herald has announced the release of new interviews with SuperBuzz, HAVN Life Sciences and RevoluGROUP discussing their late...
VANCOUVER, British Columbia, July 29, 2022 (GLOBE NEWSWIRE) -- HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company” or "HAVN Life") a biotechnology company pursuing standardi...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
